Clinical Trial Update: Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 4]

View source ↗

Summary

Phase 4 safety and tolerability trial evaluating the combination of pirfenidone and nintedanib in idiopathic pulmonary fibrosis. The study has completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)
• OFEV (Nintedanib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Phase 4 | Status: COMPLETED | Results posted: 2018-06-13